These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23030781)

  • 1. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
    Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
    APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
    APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
    Almasi CE; Christensen IJ; Høyer-Hansen G; Danø K; Pappot H; Dienemann H; Muley T
    Lung Cancer; 2011 Dec; 74(3):510-5. PubMed ID: 21640427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
    Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
    Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
    Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
    Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
    Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
    Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
    Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
    Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
    Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
    Di Bernardo MC; Matakidou A; Eisen T; Houlston RS;
    Lung Cancer; 2009 Aug; 65(2):237-41. PubMed ID: 19117638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
    Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
    Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.